Seroprevalence of Toxoplasma gondii in Immunocompromised cancer patients in Basrah Provence, Southern Iraq
Basrah Researches Sciences · 2022
DOI: 10.56714/bjrs.48.2.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basrah Researches Sciences, 2022. Verfasst von Shams AL-Duha E. Jaffer und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The current study was conducted in Basrah province during the period from Dec. 2020 to Oct. 2021. The purpose of the study was to determine the seroprevalence of IgG and IgM antibodies of toxoplasmosis in cancer patients in Basrah province, southern Iraq, using the enzyme-linked immunosorbent assay (ELISA). This study was conducted on 173 people, including 123 people with cancer who were taking chemotherapy and 25 healthy people as a first control group and 25 people with cancer who were not taking chemotherapy were considered as a second control group. The results showed that the incidence of chronic) IgG) toxoplasmosis was 31 and acute (IgM) toxoplasmosis was 0.8%.
Zitieren
APA
Jaffer, S. A. E., & Awad, A. H. H. (2022). Seroprevalence of Toxoplasma gondii in Immunocompromised cancer patients in Basrah Provence, Southern Iraq. Basrah Researches Sciences. https://doi.org/10.56714/bjrs.48.2.6
Vancouver
Jaffer SAE, Awad AHH. Seroprevalence of Toxoplasma gondii in Immunocompromised cancer patients in Basrah Provence, Southern Iraq. Basrah Researches Sciences. 2022. doi:10.56714/bjrs.48.2.6
BibTeX
@article{Jaffer2022,
author = {Jaffer, Shams AL-Duha E. and Awad, Abdul Hussein H.},
title = {Seroprevalence of Toxoplasma gondii in Immunocompromised cancer patients in Basrah Provence, Southern Iraq},
journal = {Basrah Researches Sciences},
year = {2022},
doi = {10.56714/bjrs.48.2.6}
}
EUVIMED